This information is intended for US healthcare professionals to access current scientific information about J&J Innovative Medicine products. It is prepared by Medical Information and is not intended for promotional purposes, nor to provide medical advice.
OPSYNVI® (macitentan and tadalafil)
Medical Information
OPSYNVI - The A DUE Phase 3 Trial
Last Updated: 04/07/2026
Summary
- OPSYNVI®
(macitentan and tadalafil) – The A DUE Phase 3 Trial - Minimum requirement to access interactive content: Adobe Acrobat Reader
- The executive summary infographic of the iPDF content is provided below
